“A drug that can both decrease the risk for diabetes along with the risk for having a heart attack or stroke could be a turning point in our ability to safely treat this growing population in the U.S. and abroad,” one researcher said.

The upfront costs may be higher, but new data presented at TCT 2026 showed that treating asymptomatic patients with TAVR instead of clinical surveillance was a highly cost-effective intervention. 

The prospective trial will include up to 585 patients in the United States, Canada and Europe. 

Alasnag, a veteran interventional cardiologist and women's health advocate, has won the 2027 Dr. Carolyn McCue Award for Woman Cardiologist of the Year. She directs the cardiac cath lab at King Fahd Armed Forces Hospital in Jeddah, Saudi Arabia.

The new device can treat varying anatomies and is able to compensate for native leaflet abnormalities. It was also designed to be gentle on a patient's anatomy.

Self-expanding valves, a history of stroke, renal dysfunction and nontransfemoral access were all linked to an increased risk of in-hospital stroke after TAVR. “Despite advances in valve design and technique, the overall stroke rate has plateaued,” researchers wrote.

Getting nurses and technologists more involved is a smart way to ensure new cardiac CT programs deliver the safest, most effective patient care possible.

The Center for Healthcare Quality and Payment Reform believes many physicians participating in the new Ambulatory Specialty Model could end up experiencing a pay cut. In addition, it could drive some specialists to stop treating heart failure patients altogether.

The FDA previously warned that certain Impella heart pump controllers may need hardware, firmware and/or software updates. The agency has now categorized the issue as a Class I recall. The devices should be removed from where they are used or sold until they can be serviced, but they can still be used if necessary to ensure patients receive care.

The healthcare giant's shift in strategy puts an increased focus on systems used by electrophysiologists and interventional cardiologists to manage and treat cardiovascular disease.

New codes for these technologies have made a world of difference for clinicians. Reimbursement for the use of AI is an area where cardiology is far ahead of most other healthcare specialties.

Atherectomy is still the go-to treatment option for many clinicians, but peripheral IVL appears to be gaining momentum as time goes on. 

The company posted a letter online addressed to AI-powered personal assistants, welcoming them onto its healthcare access platform—as long as they’re registered and play by the rules.

Researchers will use Meta's AI tools to explore new approaches to chest X-ray reporting, early heart failure risk prediction and Alzheimer’s disease diagnosis.